Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Financing Cancer

Shanghai Kick-Starts New Consortium To Develop First-In-Class Cancer Drugs

  • Analysis

Executive Summary

A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.

You may also be interested in...



Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Hengrui, BeyondSpring In Arbitration Face-Off After Cancer Deal Setbacks

A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.

Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy

Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.

Table

View full table

Topics

Related Companies

Tags:
China Financing Cancer
Latest Headlines

Novo Nordisk Looks To Bring AI/ML To Cardiometabolic Disease In Valo Health Deal

Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS

Pierre Fabre Continues Oncology R&D Push

Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success

See All
UsernamePublicRestriction

Register

SC145247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By